Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy

Novartis Pharmaceuticals13 enrolled

Overview

This study will evaluate the efficacy of BGG492 in reducing the sensitivity to flashing lights of patients with photosensitive epilepsy, using EEG as a readout.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Photosensitive Epilepsy

Interventions

BGG492DRUG

PlaceboDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosis of photosensitive epilepsy Exclusion Criteria: \- inconsistent photoparoxysmal response when stimulated by photic stimulation Other protocol-defined inclusion/exclusion criteria may apply.

Locations (4)

Novartis Investigator Site

Bielefeld, Germany

Novartis Investigator Site

Kehl-Kork, Germany

Novartis Investigator Site

Kiel, Germany

Novartis Investigator Site

Radeberg, Germany

Outcomes

Primary Outcomes

Outcome Measure: Photoparoxysmal response (PPR) and standardized photoparoxysmal response (SPR) determined by EEG on all treatment days.

Time frame: Days 1, 2 and 3

Secondary Outcomes

Outcome Measure: Safety and tolerability of BGG492 in patients with photosensitive epilepsy

Time frame: From Day 1 until Day 33 after treatment start.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.